Aprea Therapeutics, Inc. Stockholders Equity

Quick Answer

Aprea Therapeutics, Inc. reported Stockholders Equity of $12.44 million for fiscal year 2025.

Aprea Therapeutics, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $12.44M -35.6%
2024 $19.31M +13.9%
2023 $16.95M -33.9%
2022 $25.64M -48.2%
2021 $49.51M -36.0%
2020 $77.40M -37.7%
2019 $124.24M +341.5%
2018 -$51.44M -43.8%
2017 -$35.77M -66.6%
2016 -$21.47M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $10.91M -50.3% -18.6%
June 30, 2025 $13.41M -47.5% -13.7%
March 31, 2025 $15.55M -46.2% -19.5%
December 31, 2024 $19.31M +13.9% -12.0%
September 30, 2024 $21.95M +8.2% -14.1%
June 30, 2024 $25.56M +9.1% -11.6%
March 31, 2024 $28.92M +9.2% +70.6%
December 31, 2023 $16.95M -33.9% -16.4%
  • Aprea Therapeutics, Inc. showed a decrease of -35.6% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2016–2025 period, Aprea Therapeutics, Inc.’s stockholders equity has grown by 158.0% (from -$21.47 million to $12.44 million).
  • The most recent figure is from Aprea Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment